- 3 years ago
Chris MacLeod is a Partner in the law firm Cambridge LLP, www.cambridgellp.com. He also has Cystic Fibrosis and chairs the Canadian Cystic Fibrosis treatment Society. He talks about his life as a prominent lawyer living with cystic fibrosis and his work as the chair of the Society. He explains his success in advocating for recognition of the new cystic fibrosis medication, Kalydeca. He describes what he sees as most challenging of the challenges associated with access, disparity, and inequity as these relate to medications of demonstrable value in the treatment of cystic fibrosis. He highlights ways in which advocacy confronts the challenges he identifies. He says what more he would like to do through the Canadian Cystic Fibrosis treatment Society and to see done by others to strengthen advocacy for access to cystic fibrosis medications. He comments on the value to the cystic fibrosis community of archiving more discussions like the present one.